Omaveloxolone：費氏運動失調症(Friedreich's ataxia) 患者福音美國FDA 核准 ...
費氏運動失調症(Friedreich's ataxia) 患者福音美國FDA 核准 ...
2023年3月3日—Omaveloxolone是Nrf2(nuclearfactorerythroid2-relatedfactor2)活化劑，Nrf2在細胞中調控抗氧化作用，活化Nrf2有助抑制氧化壓力恢復細胞正常代謝 ...。其他文章還包含有：「agroundbreakingmilestoneasthefirstFDA」、「DiscoverSKYCLARYS®(omaveloxolone)OfficialPatientSite」、「Omaveloxolone」、「Omaveloxolone(oralroute)」、「Omaveloxolone」、「Omaveloxolone」、「Omaveloxolone」、「Omaveloxolone:U...
查看更多 離開網站
a groundbreaking milestone as the first FDA
https://www.cell.com
The FDA has recently approved omaveloxolone – a potent activator of nuclear factor erythroid 2-related factor 2 (NRF2) – as the first treatment for FA.
Discover SKYCLARYS® (omaveloxolone) Official Patient Site
https://www.skyclarys.com
SKYCLARYS is used for the treatment of Friedreich ataxia (FA) in adults and children aged 16 years and older.
Omaveloxolone
https://en.wikipedia.org
Omaveloxolone, sold under the brand name Skyclarys, is a medication used for the treatment of Friedreich's ataxia. It is taken by mouth.
Omaveloxolone (oral route)
https://www.mayoclinic.org
Omaveloxolone is used to treat Friedreich's ataxia. Friedreich's ataxia is a rare genetic disorder that affects the brain, spinal cord, and ...
Omaveloxolone
https://pubchem.ncbi.nlm.nih.g
Omaveloxolone is a semi-synthetic triterpenoid drug. It is an Nrf2 activator that is approved for the treatment of Friedreich's ataxia in adults and ...
Omaveloxolone
https://www.sciencedirect.com
Omaveloxolone represents the first FDA-approved drug for Friedreich's ataxia (FA). Omaveloxolone targets nuclear factor erythroid 2-related factor 2 (NRF2), ...
Omaveloxolone
https://pubmed.ncbi.nlm.nih.go
Omaveloxolone (SKYCLARYS™) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being ...
Omaveloxolone: Uses
https://go.drugbank.com
Omaveloxolone is a semisynthetic triterpenoid used to treat Friedreich's ataxia in adults and adolescents 16 years and older.
Skyclarys
https://www.ema.europa.eu
Skyclarys is a medicine used in patients aged 16 years and older to treat Friedreich's ataxia, an inherited disease that causes damage to the nervous system.